Prognostic value of myeloperoxidase in coronary artery disease: Comparison of unstable and stable angina patients

Coronary Artery Disease

Volumn 21, Issue 3, 2010, Pages 129-136

  Roman, Raquel Melchior ^a   Camargo, Paulo Vicente ^a   Borges, Flávia Kessler ^a   Rossini, Ana Paula ^a   Polanczyk, Carisi Anne ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Acute coronary syndrome; C reactive protein; Inflammation; Myeloperoxidase; Stable angina

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PEROXIDASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 77951296825     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328333f50d     Document Type: Article

References (64)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
3. Naruko T, Ueda M, Haze K, Van der Wal A, Van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106:2894-2900.
4. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347:5-12.
5. Hansson GK. Inflammation, atherosclerosis and coronary disease. N Engl J Med 2005; 352:1685-1695.
6. Arnhord J. Free radicals-friends or foes? Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Moscow) 2004; 69:8-15.
7. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94:437-444.
8. Zhang R, Brennan M, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286:2136-2142.
9. Brennan ML, Hazen S. Emerging role of myeloperoxidase an oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003; 14:353-359.
10. Nicholls SJ, Hazen SL. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis 2004; 57:S21-S22.
11. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 1996; 27:611-616.
12. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108:1440-1445.
13. Brennan ML, Penn M, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349:1595-1604.
14. Polanczyk CA, Schneid S, Imhof BV, Furtado M, Pithan C, Rohde LE, et al. Impact of redefining acute myocardial infarction on incidence, management and reimbursement rate of acute coronary syndromes. Int J Cardiol 2006; 107:180-187.
15. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to clinical and public health practice, report from the laboratory science discussion group. Circulation 2004; 110;e545-e549.
16. Smith SC Jr, Anderson JL, Cannon RO 3rd, Fadl YY, Koenig W, Libby P, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to clinical and public health practice, report from the clinical practice discussion group. Circulation 2004; 110:e550-e553.
17. Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease. JAMA 2001; 26:2154-2156.
18. Naghavi M, Libby P, Falk E, CasscellsW, Litovsky JR, Badimon JJ, et al. From vulnerable plaque to vulnerable patient. Circulation 2003; 108:1664-1672.
19. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51:810-824. (Pubitemid 40577917)
20. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. J Am Coll Cardiol 2006; 48:1-11.
21. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 1102:1111.
22. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular diasease. Pharm Therap 2006; 111:16-26.
23. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999; 85:950-958.
24. Zhang R, Shen Z, Nuseef WM, Hazen SL. The role of myeloperoxidase in the initiation of lipid peroxidation in plasma as studied in neutrophils isolated from myeloperoxidase deficient subjects. Blood 2002; 99:1802-1810.
25. Zhang R, Brennan ML, Shen Z, Hazen SL. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002; 277:46116-46122.
26. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and aterosclerosis. Free Radic Biol Med 2000; 28:1717-1725.
27. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000; 275:37524-37532.
28. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296:2391-2394.
29. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110:1134-1139.
30. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004; 24:1143-1146.
31. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating-factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158:879-891.
32. Sugiyama S, Kygiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression. Arterioscler Thromb Vasc Biol 2004; 24:1309-1314.
33. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276:41279-41287.
34. Ndrepepa G, Braun S, Mehilli J, Von Beckerath N, Schömig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008; 38:90-96.
35. Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29:1096-1102.
36. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007; 99:1364-1368.
37. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008; 155:356-360.
38. Gach O, Biémar C, Mys M, Deby-Dupont G, Chapelle JP, Deby C, et al. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Cor Art Dis 2005; 16:59-65.
39. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalouschek W, et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006; 47:2212-2218.
40. Leong L, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006; 152:94-101.
41. Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, et al. Plasma Myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006; 98:796-799.
42. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363.
43. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reative protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349:462-466.
44. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, et al. C-reactive protein as a marker of cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 1999; 83:1595-1599.
45. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331:417-424.
46. Morrow DA, Rifai N, Antman EM,Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy thrombolysis in myocardial infarction. J Am Coll Cardiol 1998; 31:1460-1465.
47. Lindahl B, Toss H, Siegbahn A, Venge P,Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. N Engl J Med 2000; 343:1139-1147.
48. Duarte ER, Pellanda LC, Portal VL. Inflammatory, lipid and metabolic profile in acute ischemic syndrome: correlation with hospital and post-hospital events. Arq Bras Cardiol 2005; 84:122-129.
49. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. PROVE IT-TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
50. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46:1405-1410.
51. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
52. Manenti ER, Bodanese LC, CameY SA, Polanczyk CA. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin Cardiol 2006; 29:405-410.
53. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome. J AmColl Cardiol 2003; 41:916-924.
54. Oltrona L, Ottani F, Galvani M. Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J 2004; 148:405-415.
55. Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978; 61:235-242.
56. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004; 8: 234-242.
57. Steeghs N, Goekoop RJ, Niessen RW, Jonkers GJ, Dik H, Huisman MV. C-reactive protein and D-dimer with clinical probability score in the exclusion of pulmonary embolism. Br J Haematol 2005; 130:614-619.
58. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke 2005; 36:1316-1329.
59. Zhou Tao, Zhou S, Qi S, Shen X, Zeng G, Zhou H. The effect of atorvastatin on serym myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 2006; 368:168-172.
60. Chang P, Wu T, Hung C, Tsao K, Sun C, Wu LL, et al. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation. Clin Chim Acta 2006; 373:158-163.
61. Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008; 54:1076-1079.
62. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001; 142:336-339.
63. Asselbergs FW, Reynold WF, Cohen-Tervaert JW, Jessurun GAJ. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004; 116:429-430.
64. Chevrier I, Trefouet DA, Massonnet-Castel S, Beaune P, Loriot MA. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis? Atherosclerosis 2006; 188:150-154.